Quarterly report
Open the filing on sec.gov
XBiotech Inc. (XBIT)
Nasdaq: XBIT · Pharmaceutical Preparations · Austin, TX · filing with the SEC since 2014
The companyfiscal 2023, as filed
Revenue$0.00-100.0%
Net income-$24.6M+25.4%
Earnings per share$-0.81+25.0%
Operating cash flow-$18.7M-26.3%
Cash$200M+27.2%
Debtn/a
Shareholders’ equity$219M-9.0%
Shares, diluted30.4M-0.0%
Return on equity-32.5%
The recordfrom its filings
Filings in 202614
Newest filingNov 12 · 10-Q
Annual reportMar 13, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$700,000
Patents granted33
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Net income -$43.6MCash from operations -$41.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Annual report to shareholders
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Annual report, amended
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.